Select Page

We modify protein interactions to offer treatments where current therapies fail

Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases

We are building a portfolio of protein interaction-modifying small molecules against resistant cancers and rare diseases

 Our first program leverages a dual mechanism with killing cancer cells and activating an anti-tumoral immune response